Evicenter
P&T meetings

Tinlarebant

Stargardt disease type 1

Also known as LBS-008
Manufacturer
Belite Bio
Regulatory submission
NDA submitted June 2026
66 sources

Section 6 of 6

References

66 sources

  1. Abu Serhan et al. (2026) (opens in a new tab)
  2. American Academy of Ophthalmology (2022) (opens in a new tab)
  3. ANZCTR ACTRN12624000031561 (opens in a new tab)
  4. ARVO Annual Meeting (2023) (opens in a new tab)
  5. Aziz et al. (2021) (opens in a new tab)
  6. Belite Bio (opens in a new tab)
  7. Belite Bio (2023) (opens in a new tab)
  8. Belite Bio (2024) (opens in a new tab)
  9. Belite Bio (2025) (opens in a new tab)
  10. Belite Bio (2025) (opens in a new tab)
  11. Belite Bio (2026) (opens in a new tab)
  12. Belite Bio (2026) (opens in a new tab)
  13. Belite Bio (2026) (opens in a new tab)
  14. Belite Bio (2026) (opens in a new tab)
  15. Belite Bio (2026) (opens in a new tab)
  16. Belite Bio (2026) (opens in a new tab)
  17. Belite Bio (2026) (opens in a new tab)
  18. Belite Bio Commercial Day (2026) (opens in a new tab)
  19. Belite Bio company presentation (2026) (opens in a new tab)
  20. Belite Bio Form 20-F (2026) (opens in a new tab)
  21. Bernstein et al. (2026) (opens in a new tab)
  22. Bodenbender et al. (2025) (opens in a new tab)
  23. Britten-Jones et al. (2025) (opens in a new tab)
  24. Cioffi (2025) (opens in a new tab)
  25. ClinicalTrials.gov NCT05244304 (opens in a new tab)
  26. ClinicalTrials.gov NCT05266014 (opens in a new tab)
  27. ClinicalTrials.gov NCT06388083 (opens in a new tab)
  28. Dayma et al. (2025) (opens in a new tab)
  29. Edwards et al. (2026) (opens in a new tab)
  30. FDA Orphan Drug Designations and Approvals (2017) (opens in a new tab)
  31. Federspiel et al. (2018) (opens in a new tab)
  32. Fujinami et al. (2024) (opens in a new tab)
  33. Gomes et al. (2022) (opens in a new tab)
  34. Gong et al. (2021) (opens in a new tab)
  35. Grigg et al. (2022) (opens in a new tab)
  36. Grigg et al. (2023) (opens in a new tab)
  37. Grigg et al. (2024) (opens in a new tab)
  38. Hoang et al. (2026) (opens in a new tab)
  39. Ibukun et al. (2026) (opens in a new tab)
  40. Kay et al. (2026) (opens in a new tab)
  41. Knott et al. (2023) (opens in a new tab)
  42. Kong et al. (2018) (opens in a new tab)
  43. Kootstra et al. (2026) (opens in a new tab)
  44. Mata et al. (2025) (opens in a new tab)
  45. Mayo Clinic (opens in a new tab)
  46. MedlinePlus Genetics (opens in a new tab)
  47. National Eye Institute (2024) (opens in a new tab)
  48. Ng et al. (2024) (opens in a new tab)
  49. Palmgren et al. (2026) (opens in a new tab)
  50. Parameswarappa et al. (2026) (opens in a new tab)
  51. Polasek et al. (2026) (opens in a new tab)
  52. Retina South Africa (2025) (opens in a new tab)
  53. Roborel de Climens et al. (2021) (opens in a new tab)
  54. Runhart et al. (2022) (opens in a new tab)
  55. Selleck Chemicals (opens in a new tab)
  56. Stanford Health Care (opens in a new tab)
  57. Stargardt disease patient-listening-session report (2022) (opens in a new tab)
  58. Strauss et al. (2016) (opens in a new tab)
  59. Strauss et al. (2023) (opens in a new tab)
  60. Sui et al. (2025) (opens in a new tab)
  61. Terheyden et al. (2022) (opens in a new tab)
  62. UCSF Health (opens in a new tab)
  63. UK Health Research Authority (opens in a new tab)
  64. UK Health Research Authority (2021) (opens in a new tab)
  65. Vaccaro et al. (2023) (opens in a new tab)
  66. Waugh et al. (2018) (opens in a new tab)